Plasma miR-371a-3p Predicts Recurrence in Stage I Testicular Cancer: Interim Results From the CLIMATE Study - Summary - MDSpire
From the Journals

Plasma miR-371a-3p Predicts Recurrence in Stage I Testicular Cancer: Interim Results From the CLIMATE Study

In the management of stage I testicular cancer, a persistent clinical dilemma is the identification of patients who truly need adjuvant treatment after orchiectomy rather than active surveillance alon...

  • By

  • Caroline Helwick

  • May 6, 2026

  • 11 min

Share

The interim results from the CLIMATE study indicate that post-orchiectomy plasma miR-371a-3p serves as a superior biomarker compared to existing methods for assessing measurable residual disease (MRD) in patients with stage I testicular cancer. Conducted across Australia and New Zealand, the study enrolled 200 patients and showed that miR-371 could enhance patient selection for adjuvant chemotherapy, potentially reducing unnecessary treatment. Key findings suggest that miR-371 positivity correlates with a significantly increased risk of recurrence, urging the need for improved risk stratification in clinical settings.

Original Source(s)

Plasma miR-371a-3p Predicts Recurrence in Stage I Testicular Cancer: Interim Results From the CLIMATE Study

  • by Caroline Helwick

  • May 6, 2026

Related Content

One Pathway for Esophageal Cancer?

Molecular profiling reveals precursor signals in BE-negative esophageal cancer

  • May 7, 2026

  • 2 min
‘Promising’ Signal Only: ctDNA in Early Breast Cancer Not Yet Ready for Clinical Use

Despite compelling prognostic associations across multiple retrospective data sets, no interventional trial has demonstrated that acting on circulating tumor DNA testing results in early breast cancer...

Experimental Daraxonrasib Shows Promise in Advanced Pancreatic Cancer

Metastatic pancreatic ductal adenocarcinoma remains one of the most challenging malignancies to treat in clinical oncology.

  • by

  • May 6, 2026

  • 5 min